|
HEALTH CARE INNOVATION PUBLICATIONS
“Improving Value: Health +
Care in the UK.” Business
Strategy Review, vol. 22, issue 1, 2011.
“Dinero
habló con esta profesora de la
Universidad de Virginia.”
Dinero Magazine, August 12, 2010.
“Ein Qualitätswettbewerb
senkt die kosten [Competition on Quality Lowers Costs].”
Interviewed by Urs P. Gasche, CSS Magazin,
March 2009. [Translated and published simultaneously in the
German, French, and Italian editions of the magazine].
“Creating a High Value Delivery System for Health Care.”
Seminars in Thoracic and Cardiovascular Surgery,
Spring 2009, vol. 21, no. 1, pp. 35-42. Co-authored with Scott Wallace.
“Testimony of Elizabeth Olmsted Teisberg before the Senate
committee on Health, Education, Labor and Pensions."
Congressional Record, January 29, 2009. Written testimony is available at:
http://www.isc.hbs.edu/pdf/20090129_Tesiberg_Senate_Testimony.pdf.
“Health
Stewardship: The Responsible Path to a Healthier Nation.”
by the Aspen Institute, 2009. Co-authored with Scott
Wallace, on behalf of the advisory committee for the Aspen
Health Stewardship Project.
“Opportunities for Value-Based Competition in Swiss Health
Care.” July 10, 2008. Published in German: Nutzenorientierter Wettbewerb im schweizerischen
Gesundheitswesen: Möglichkeiten und
Chancen.
“Rethinking the Role of
Employers.” Financial Times.com, July 3, 2008.
Co-authored with Michael E. Porter and Scott Wallace.
“HEALTH REFORM: Redefining Health Care.”
Heath
Affairs Blog, March 23, 2007. Coauthored
with Michael E. Porter.
“How
Physicians Can Change the Future of Health Care.”
Journal of the American Medical Association, JAMA.
2007;297:1103-1111, March 14, 2007. Co-authored with Michael
E. Porter.
“Driving Improvement in Value for Patients.” Online
Exclusive, The Cerner Quarterly, vol. 2, no.
3, 2006. http://www.cerner.com/public/CernerQuarterly.asp?id=27750.
Interview: “Michael Porter and Elizabeth Teisberg on
Redefining Value in Health Care: An Interview.” Interviewed
by Alistair Davidson and Robert M. Randall, Strategy
and Leadership, vol. 34, no.6, 2006, pp. 48-50.
“Doctor Know: Information Is The Best Medicine.” The
New Republic, July 2006. Co-authored with Michael
Porter.
Redefining Health Care: Creating Value Based
Competition on Results. Harvard Business School
Press. May 2006. Co-authored with Michael E. Porter.
“Redefining Competition in Health Care.” Harvard
Business Review, June 2004, pp. 64-77.
Co-authored with Michael E. Porter.
“Fixing Competition in U.S. Health Care.” HBR Research
Report, June 2004, Product number 7081. Co-authored
with Michael E. Porter.
A Script - Innovation Is the Key. EIU Healthcare
International, Economist Intelligence Unit Limited,
1st Quarter 1997, pp. 79-88. Co-authored with Gregory B.
Brown.
“Building on Strength: Upgrading the Medical Device Cluster
in Massachusetts.” Governor’s Council on Economic Growth and
Technology, prepared for Governor Weld of
Massachusetts with the assistance of Yiannis
Monovoukas and Scott Wilkin, March 1995. (This work with
about 15 CEOs led to the formation of Mass Medical, the
state’s medical device industry association.)
“Making Competition in Health Care Work.” Harvard
Business Review, July-August 1994, vol. 72, no. 4,
pp. 131-141. Co-authored with Michael E. Porter and Gregory
B. Brown.
“The Role of Biomedical Research in Health Care Reform.”
Science, October 7, 1994. Co-authored with M.W.
Kirschner and Elizabeth Marincola.
“Innovation: Medicine's Best Cost-Cutter.” Viewpoints
column. The New York Times, February 27, 1994.
Co-authored with Michael E. Porter and Gregory B. Brown.
“The Debate on Health Care Reform Continues.” Harvard
Business Review, November-December 1994. Co-authored
with Michael E. Porter and Gregory B. Brown.
“Finding a Lasting Cure for U.S. Health Care.” Perspectives
column. Harvard Business Review,
September-October 1994. Co-authored with Michael E. Porter
and Gregory B. Brown.
STRATEGY AND REAL OPTIONS PUBLICATIONS
The Portable MBA, Fourth Edition. John
Wiley & Sons, Inc., New York, 2003. Co-authored with R.F.
Bruner, M.R. Eaker, R.E. Freeman, R.E. Spekman and S.
Venkataraman.
“Sustainable Business: Opportunity and Value Creation.”
INTERFACES, May-June 2000, 30, no. 3, pp. 1-12.
Co-authored with A. Larson and R. Johnson.
Special Issue of INTERFACES on Sustainable Business.
May-June 2000. Co-editor with A. Larson.
“Introduction: Strategy, Modeling and Analysis.”
INTERFACES, November-December 1999, 29, no. 6, pp.
1-3. Co-authored with S. Bodily.
Special Issue of INTERFACES on Strategy, Analysis and
Models. November-December 1999, 29, no. 6. Co-editor
with S. Bodily.
The Portable MBA, Third Edition. John
Wiley & Sons, Inc., New York, 1998. Co-authored with R.F.
Bruner, M.R. Eaker, R.E. Freeman, and R.E. Spekman.
Translated into Japanese (1998), Portuguese (1999), Chinese
(1999) and Russian (2000).
“Methods for Evaluating Capital Investment Decisions Under
Uncertainty.” Real Options in Capital Investment:
New Contributions. Edited by Lenos Trigeorgis.
Westport, CT: Praeger Publishing, 1995.
“An Option Valuation Analysis of Investment Choices by a
Regulated Firm.” Management Science, April
1994, vol. 40, no. 4, pp. 535-548.
“Capital Investment Strategies Under Uncertain Regulation.”
The RAND Journal of Economics, Winter 1993,
vol. 24, no. 4, pp. 591-604.
“The Value of Commodity Purchase contracts with Limited
Price Risk.” The Energy Journal, 1991, vol.
12, no. 3, pp. 109-135. Co-authored with Thomas J. Teisberg.
“When Choosing R&D Projects, Go with Long Shots.”
Research-Technology Management, January-February
1991. Co-authored with A.L. Kolbe and P.A. Morris.
“Investment Cost Recovery and Incentives for Power Plant
Construction.” Public Utilities Fortnightly,
March 3, 1988, vol. 121, no. 5, pp. 9-14.
“Evaluating the Effects of Time and Risk on Investment
Choices: A Comparison of Finance and Decision Analysis.”
Electric Power Research Institute Project,
2379-4, January 1987. Co-authored with A.L. Kolbe and P.A.
Morris.
OTHER PUBLICATIONS
“Managing Ideas.” Autumn 2003. Batten Briefings.
Co-authored with C. Thompson and K. Ramdas.
“Analyzing R&D and Policy Options for the Greenhouse
Effect.” The Energy Industries in Transition:
1985-2000, Part I. Edited by J.P. Weyant and D.B.
Sheffield, International Association of Energy Economists,
1984. Co-authored with B.R. Judd and L.J. Pollenz.
COURSE DEVELOPMENT MATERIALS
INNOVATION (INCLUDING HEALTH SECTOR INNOVATION)
Course on Value-Based Health Care Delivery developed
in collaboration with Professor Michael E. Porter. (See
teaching) Course development includes cases, lectures,
teaching plans, teaching notes and videos of case
protagonists. The first five cases below address
Redefining Health Care.
The Cleveland Clinic
Growth Strategy 2008, HBS no. 9-709-473, 2009, REV. February
1, 2010
Co-authored
with Michael E. Porter
The Joslin
Diabetes Center, HBS no. 9-710-424, 2009, REV. January 25,
2010.
Co-authored
with Michael E. Porter and Scott Wallace
International Diabetes Center at Park Nicollet, forthcoming
HBS case.
Co-authored
with Michael E. Porter
Novo Nordisk
in 2009, forthcoming HBS case.
Co-authored
with Scott Wallace and Michael E. Porter
Park
Nicollet Health Services: Diabetes Care, forthcoming HBS
case.
Co-authored
with Michael E. Porter
Magnetic
Surgery System (A)
December
1999, UVA-OM-0888
Magnetic
Surgery System: B, C, D and E
December
1999, UVA-OM-0889, 0890, 0891 and 0892
Managing
Innovation at GE Medical Systems (A)
December
1998, UVA-OM-0882
Managing
Innovation at GE Medical Systems (B)
1999,
UVA-OM-0883
Option
Valuation: Insights and Explanations Using a Binomial
Approach
July 1999,
UVA-OM-0900
Seaflower
Associates, Inc.: Valuing Venture Capital with Real Options
January,
1999, UVA-OM-0884
Active
Coatings, Inc. (A) - Challenges in Managing Product
Development
February
1996, Harvard Business School, no. 9-796-061
Active
Coatings, Inc. (B) - Challenges in Managing Product
Development
February
1996, Harvard Business School, no. 9-796-062
Note on the
FDA Approval Process for Medical Devices
November
1995, Harvard Business School, no. 9-796-063 13
Zoll Medical Corporation
December
1994, Harvard Business School, no. 9-795-053
Zoll Medical
Corporation (B), (C) and (D)
December
1994, Harvard Business School, no. 9-795-054, no. 9-795-055,
and no. 9-796-078
Alpha-Beta
Technology, Inc., Pioneering Carbohydrate Technology
February,
1994, Harvard Business School, no. 9-794-093
Alpha-Beta
Technology, Inc. (B): Trials with Betafectin
December,
1994, Harvard Business School, no. 9-795-045
Diagnosis
for the Future: The Genetic Testing Industry in 1993
February
1994, Harvard Business School, no. 9-794-053
IG Laboratories Inc. (A): Pursuing the Future of Genetic
Testing
October
1994, Harvard Business School, no. 9-794-054
IG
Laboratories, Inc. (B): The Paradox of Growth – 1993-94
February
1996, Harvard Business School, no. 9-796-114
Genzyme Corporation
April 1993,
Rev. May 1994, Harvard Business School, no.9-793-120 and TN
no. 5-793-122
Biotechnology Strategies in 1992
April 1992, Rev. June 1993, Harvard
Business School, no.9-792-082 and TN no. 5-793-036
|